Cytox Group Limited is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease.
Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ interpretive software for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform from Thermo Fisher Scientific, Cytox offers genomic profiling testing assays and services to early access collaborators in academia and biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.
This investment from Maven is a strong endorsement of Cytox and our technology to improve success rates in the development of new Alzheimer’s drugs.
Dr Richard Pither, CEO of Cytox Group
